Monitor · Newsflow
Market news
Equities, fixed income, macro, central-bank and regulator flow — every item sentiment-scored, impact-ranked and ticker-tagged.
- The Motley Fool·Jun 20, 2026Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?
- Zacks Investment Research·Jun 19, 2026HIGHPFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed
- The Motley Fool·Jun 18, 2026HIGHStock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook
- Zacks Investment Research·Jun 18, 2026HIGHPfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
- Benzinga·Jun 18, 2026HIGHPfizer Stock Drops Today As CFO Steps Down In August
- Zacks Investment Research·Jun 18, 2026Can Pfizer Take Share From Lilly & Novo Nordisk in the Obesity Space?
- Reuters·Jun 18, 2026Pfizer CFO Dave Denton to step down, leave company in August
- Seeking Alpha·Jun 17, 2026HIGHPfizer: Why I'm Still Expecting A Massive Rebound
- Fool - Investing News·Jun 15, 2026HIGHHere's When Pfizer's CEO Says the Company Might Get Back to Generating High-Single-Digit Growth
- Zacks Investment Research·Jun 15, 2026HIGHIs Pfizer's Discounted Valuation a Buying Opportunity or a Value Trap?
- Zacks Investment Research·Jun 15, 2026Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
- Zacks Investment Research·Jun 11, 2026HIGHPfizer (PFE) Outpaces Stock Market Gains: What You Should Know
- 24/7 Wall Street·Jun 11, 2026HIGHThis $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It's a Flawless Safe-Haven for Retirees
- 24/7 Wall Street·Jun 11, 2026MEDA Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25
- Reuters·Jun 10, 2026HIGHPfizer CEO warns German investment at risk over drug pricing policies
- 24/7 Wall Street·Jun 10, 2026HIGHPrediction: Pfizer Stock Will Double on This Date
- Zacks Investment Research·Jun 09, 2026HIGHAmneal and Pfizer GLP-1 Deal: New Growth Lever?
- Zacks Investment Research·Jun 09, 2026HIGHPFE Gets FDA Nod for Expanded Use of Hemophilia Drug Hympavzi
- Seeking Alpha·Jun 08, 2026Pfizer Inc. (PFE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- Seeking Alpha·Jun 08, 2026HIGHWall Street Breakfast Podcast: Pfizer Chases Monthly Edge
- Reuters·Jun 08, 2026HIGHUS FDA approves Pfizer's bleeding disorder drug for children
- The Motley Fool·Jun 07, 2026HIGH3 Dividend Stocks to Buy Hand Over Fist in June
- The Motley Fool·Jun 06, 2026HIGHCan Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer.
- The Motley Fool·Jun 06, 2026HIGHPfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems
- Business Wire·Jun 06, 2026HIGHRobust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide
- Business Wire·Jun 06, 2026HIGHRobust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide
- Zacks Investment Research·Jun 04, 2026MEDWhy Is Pfizer (PFE) Down 4.5% Since Last Earnings Report?
- Seeking Alpha·Jun 03, 2026Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
- 24/7 Wall Street·Jun 03, 2026MEDPfizer vs Merck: Chasing High Yield vs Higher Returns
- Zacks Investment Research·May 13, 2026HIGHCan Pfizer Achieve High Single-Digit Revenue CAGR From 2029?
- Seeking Alpha·May 12, 2026MEDPfizer: Don't Pass On This Dirt-Cheap Buying Opportunity
- Fool - Investing News·May 12, 2026HIGHPrediction: Pfizer Will Beat the Market Over the Next 5 Years
- Reuters·May 12, 2026HIGHRigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug
- The Motley Fool·May 12, 2026HIGHPfizer's Net Income Drops in Q1. Is Its Dividend Still Safe?
- 24/7 Wall Street·May 04, 2026Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era
- Seeking Alpha·May 01, 2026HIGHPfizer: Why You Should Double Down Into Q1